As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
ApexOnco Front Page
Recent articles
Summit and Nuvalent have scored prized plenary spots.
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
A royalty financing deal should see this gene therapy launched nine months after its surprise US approval.
Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.
A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.